SCHEMBL3092340

SCHEMBL3092340

NCc1c(-c2ccc(Cl)cc2Cl)ncn1Cc1ccccc1OC(F)(F)F

nearest known ligand 0.42

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 4/20 0.42
DPP8 Q6V1X1 2/20 0.41
HSD17B13 Q7Z5P4 12/20 0.40
BCL2L2 Q92843 1/20 0.37
CNR1 P21554 1/20 0.37
P2RX7 Q99572 1/20 0.36
GRIN2B Q13224 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3092318 0.92 HSD17B13 (0.40) DPP4HSD17B13BCL2L2P2RX7GRIN2B
SCHEMBL3089977 0.87 BCL2L2 (0.50) DPP4DPP8HSD17B13BCL2L2P2RX7
SCHEMBL3084277 0.86 DPP4 (0.43) DPP4DPP8BCL2L2
SCHEMBL3092878 0.85 DPP4 (0.44) DPP4DPP8P2RX7
SCHEMBL3084580 0.84 DPP4 (0.49) DPP4DPP8CNR1P2RX7
SCHEMBL3083195 0.84 DPP4 (0.39) DPP4HSD17B13BCL2L2
SCHEMBL3087663 0.83 CNR1 (0.47) DPP4DPP8CNR1
SCHEMBL3596138 0.82 DPP4 (0.40) DPP4DPP8HSD17B13GRIN2B
SCHEMBL3091146 0.81 DPP4 (0.46) DPP4DPP8P2RX7
SCHEMBL3088192 0.80 DPP4 (0.46) DPP4DPP8P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7728146-B2 Enzyme inhibitors PROBIODRUG AG (DE) 2010-06-01 US claimed
US-20100234397-A1 ENZYME INHIBITORS PROBIODRUG AG (DE) 2010-09-16 US disclosed
US-20100234397-A1 ENZYME INHIBITORS PROBIODRUG AG (DE) 2010-09-16 US disclosed
US-20100234397-A1 ENZYME INHIBITORS PROBIODRUG AG (DE) 2010-09-16 US disclosed
US-7728146-B2 Enzyme inhibitors PROBIODRUG AG (DE) 2010-06-01 US disclosed
US-7728146-B2 Enzyme inhibitors PROBIODRUG AG (DE) 2010-06-01 US disclosed
US-7728146-B2 Enzyme inhibitors PROBIODRUG AG (DE) 2010-06-01 US disclosed
EP-2007734-A1 ENZYME INHIBITORS Probiodrug AG (DE) 2008-12-31 EP disclosed
US-20070244177-A1 ENZYME INHIBITORS PROBIODRUG AG (DE) 2007-10-18 US disclosed
US-20070244177-A1 ENZYME INHIBITORS PROBIODRUG AG (DE) 2007-10-18 US disclosed
US-20070244177-A1 ENZYME INHIBITORS PROBIODRUG AG (DE) 2007-10-18 US disclosed
WO-2007116092-A1 ENZYME INHIBITORS PROBIODRUG AG (DE) 2007-10-18 WO disclosed
WO-2007116092-A1 ENZYME INHIBITORS PROBIODRUG AG (DE) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244177-A1 ENZYME INHIBITORS ACHE, BACE1, MAOA DPP4 147/4885DPP8 464/4885HSD17B13 281/4885
US-20100234397-A1 ENZYME INHIBITORS ACHE, MAOA, BACE1 DPP4 372/4885DPP8 618/4885HSD17B13 380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.